Figure 2
Figure 2. Cdc42 confers immunoresistance of cancer in vitro. (A) The 5-hour 51Cr release assay of cA2Kb-Cdc42 (● ○) or cA2Kb-control MEFs (■ □ coincubated with allo-A2 CTLs (● ■) or A2 Flu control CTLs (○ □). Mean values plus or minus SD of 3 independent experiments are shown. (B) Clonogenic survival of cA2Kb-Cdc42 and cA2Kb-control MEFs coincubated with allo-A2 CTLs at the indicated E/T ratios (representative photograph of at least 3 independent experiments). (C) Clonogenic survival of HCT116-Cdc42 and HCT116-control human colorectal cancer cells coincubated with allo-A2 CTLs (representative photograph of 3 independent experiments).

Cdc42 confers immunoresistance of cancer in vitro. (A) The 5-hour 51Cr release assay of cA2Kb-Cdc42 (● ○) or cA2Kb-control MEFs (■ □ coincubated with allo-A2 CTLs (● ■) or A2 Flu control CTLs (○ □). Mean values plus or minus SD of 3 independent experiments are shown. (B) Clonogenic survival of cA2Kb-Cdc42 and cA2Kb-control MEFs coincubated with allo-A2 CTLs at the indicated E/T ratios (representative photograph of at least 3 independent experiments). (C) Clonogenic survival of HCT116-Cdc42 and HCT116-control human colorectal cancer cells coincubated with allo-A2 CTLs (representative photograph of 3 independent experiments).

Close Modal

or Create an Account

Close Modal
Close Modal